A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer

By Geller Melissa A.   Cooley Sarah   Judson Patricia L.   Ghebre Rahel   Carson Linda F.   Argenta Peter A.   Jonson Amy L.   Panoskaltsis-Mortari Angela   Curtsinger Julie   McKenna David   Dusenbery Kathryn   Bliss Robin   Downs Levi S.   Miller Jeffrey S.  

Cytotherapy, Vol. 13, Iss. 1, 2011-01 ,pp. : 98-107

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy

By Tam Yk   Martinson Ja   Doligosa K   Klingemann H-g  

Cytotherapy, Vol. 5, Iss. 3, 2003-01 ,pp. : 259-272

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy

By Tam Yk   Martinson Ja   Doligosa K   Klingemann H-g  

Cytotherapy, Vol. 5, Iss. 2, 2003-01 ,pp. : 259-272

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Natural killer cells: biology and application in stem-cell transplantation

By Farag SS   Fehniger T   Ruggeri L   Velardi A   Caligiuri MA  

Cytotherapy, Vol. 4, Iss. 5, 2002-09 ,pp. : 445-446

Ashgate Publishing Ltd

Access to resources Recommend Favorite

Natural killer cell alloreactivity and haplo-identical hematopoietic transplantation

By Ruggeri L   Mancusi A   Burchielli E   Aversa F   Martelli Mf   Velardi A  

Cytotherapy, Vol. 8, Iss. 6, 2006-12 ,pp. : 554-558

Ashgate Publishing Ltd

Access to resources Recommend Favorite